



Painkillers

Re-formulated & patented Diclofenac K & Na
Immediate Release formulations

- **K-Salt**
- 50mg tablets. 25mg tablets,
- 12.5mg tablets (OTC) – see below
- 50mg/ml Drops (generic acute pain), 50mg/ml Drops (migraine)
- 50mg powder (no longer available - licensed exclusively to Novartis)

- **Na Salt**
- 25mg sachet, 25mg tablets

**12,5mg Diclofenac K
Immediate Release Tablets**

Opportunity: *Global/local licensing agreement*

Product:	Active ingredient	Diclofenac Potassium Salt
	Dosage	12,5mg
	Formulation	Film Coated Immediate Release Tablets
	Indications	Short term treatment of moderate painful conditions and fever
	Classification	OTC
	Status	Registered in Germany (November 2006) and Switzerland (June 2007); under registration in Sweden, Australia and New Zealand. Mutual Recognition Procedure is ready to start, extending the granted approval to other EU countries.
Innovation	Our proprietary formulation in tablets has the main following marketing claims compared to the main diclofenac based OTC competitor Voltaren Dolo® marketed by Novartis Consumer Health: -Immediate release profile (Cmax in 21 min. compared to 29 min.) -Regularity of absorption (inter-subject variability in absorption)); -Cost competitive manufacturing process (dry mixing for direct compression)	



Advantages	This formulation has the following advantages compared with competitive products: <ul style="list-style-type: none">- Rapid absorption- Regularity of absorption The most promising marketing opportunity is Brand Strategy in the OTC field
Development Status:	Full CTD Dossier Available
Intellectual property:	Wide Patent coverage in all the major countries.